1. Home
  2. IMVT vs TPC Comparison

IMVT vs TPC Comparison

Compare IMVT & TPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMVT
  • TPC
  • Stock Information
  • Founded
  • IMVT 2018
  • TPC 1894
  • Country
  • IMVT United States
  • TPC United States
  • Employees
  • IMVT N/A
  • TPC N/A
  • Industry
  • IMVT Biotechnology: Biological Products (No Diagnostic Substances)
  • TPC General Bldg Contractors - Nonresidential Bldgs
  • Sector
  • IMVT Health Care
  • TPC Consumer Discretionary
  • Exchange
  • IMVT Nasdaq
  • TPC Nasdaq
  • Market Cap
  • IMVT 2.7B
  • TPC 2.5B
  • IPO Year
  • IMVT N/A
  • TPC N/A
  • Fundamental
  • Price
  • IMVT $15.24
  • TPC $58.40
  • Analyst Decision
  • IMVT Buy
  • TPC Strong Buy
  • Analyst Count
  • IMVT 11
  • TPC 3
  • Target Price
  • IMVT $35.88
  • TPC $60.67
  • AVG Volume (30 Days)
  • IMVT 1.2M
  • TPC 779.8K
  • Earning Date
  • IMVT 08-11-2025
  • TPC 08-06-2025
  • Dividend Yield
  • IMVT N/A
  • TPC N/A
  • EPS Growth
  • IMVT N/A
  • TPC N/A
  • EPS
  • IMVT N/A
  • TPC N/A
  • Revenue
  • IMVT N/A
  • TPC $4,770,779,000.00
  • Revenue This Year
  • IMVT N/A
  • TPC $19.51
  • Revenue Next Year
  • IMVT N/A
  • TPC $15.59
  • P/E Ratio
  • IMVT N/A
  • TPC N/A
  • Revenue Growth
  • IMVT N/A
  • TPC 12.03
  • 52 Week Low
  • IMVT $12.72
  • TPC $18.34
  • 52 Week High
  • IMVT $34.47
  • TPC $63.96
  • Technical
  • Relative Strength Index (RSI)
  • IMVT 43.58
  • TPC 69.58
  • Support Level
  • IMVT $14.50
  • TPC $53.83
  • Resistance Level
  • IMVT $15.52
  • TPC $57.75
  • Average True Range (ATR)
  • IMVT 0.69
  • TPC 2.56
  • MACD
  • IMVT -0.06
  • TPC 0.15
  • Stochastic Oscillator
  • IMVT 41.16
  • TPC 68.43

About IMVT Immunovant Inc.

Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates.

About TPC Tutor Perini Corporation

Tutor Perini Corp offers general contracting, construction management, and design-build services to private and public customers. The company constructs and repairs transportation infrastructure, water-treatment facilities, and a wide range of buildings. Tutor Perini has three operating segments: Civil, Building, and Specialty Contractors. A majority of its revenue is generated from the Civil segment, which specializes in public works construction and the replacement and reconstruction of infrastructure. Its civil contracting services include construction and rehabilitation of highways, bridges, tunnels, mass-transit systems, military and other government facilities, and water management and wastewater treatment facilities. Geographically, it derives key revenue from the United States.

Share on Social Networks: